Department of Internal Medicine, Center for Thyroid Cancer, National Cancer Center, Goyang, Korea.
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Endocrinol Metab (Seoul). 2024 Feb;39(1):61-72. doi: 10.3803/EnM.2024.1938. Epub 2024 Feb 14.
The 2023 Korean Thyroid Association (KTA) Management Guideline for Patients with Thyroid Nodules constitute an update of the 2016 KTA guideline for thyroid nodules and cancers that focuses specifically on nodules. The 2023 guideline aim to offer updated guidance based on new evidence that reflects the changes in clinical practice since the 2016 KTA guideline. To update the 2023 guideline, a comprehensive literature search was conducted from January 2022 to May 2022. The literature search included studies, reviews, and other evidence involving human subjects that were published in English in MEDLINE (PubMed), Embase, and other relevant databases. Additional significant clinical trials and research studies published up to April 2023 were also reviewed. The limitations of the current evidence are discussed, and suggestions for areas in need of further research are identified. The purpose of this review is to provide a summary of the 2023 KTA guideline for the management of thyroid nodules released in May 2023 and to give a balanced insight with comparison of recent guidelines from other societies.
2023 年韩国甲状腺协会（KTA）甲状腺结节管理指南是对 2016 年 KTA 甲状腺结节和癌症指南的更新，该指南专门针对结节。2023 年指南旨在根据自 2016 年 KTA 指南以来反映临床实践变化的新证据提供更新的指导。为了更新 2023 年指南，从 2022 年 1 月到 2022 年 5 月进行了全面的文献检索。文献检索包括在 MEDLINE（PubMed）、Embase 和其他相关数据库中以英文发表的涉及人类受试者的研究、综述和其他证据。还回顾了截至 2023 年 4 月发表的其他重要临床试验和研究。讨论了当前证据的局限性，并确定了需要进一步研究的领域的建议。本综述的目的是总结 2023 年 5 月发布的 KTA 甲状腺结节管理指南，并与其他学会的最新指南进行比较，提供一个平衡的视角。
